$0.567
+0.005 (+0.84%)收盘时
AKBA 资讯
AKBA 事件
Scynexis Appoints Steven Burke to Board of Directors
Scynexis (SCYX) announced the appointment of Steven Burke, M.D., to its Board of Directors, effective September 18, 2026. Burke worked at Akebia Therapeutics (AKBA) since 2019.
Akebia Begins Phase 2 Trial Evaluating Ebribafusp for Rare Kidney Diseases
Akebia announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for the treatment of rare complement-mediated kidney diseases, including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Ebribafusp is an investigational, next-generation anti-C3d factor H fusion protein designed to inhibit complement activation in tissues without inhibiting the complement system in the blood. The Phase 2 basket trial is open-label, and Akebia expects to report initial data in 2027.
Akebia Q2 Revenue $49.13M Beats Expectations
Reports Q2 revenue $49.13M, consensus $48.86M. "We're pleased with Vafseo's continued sequential revenue growth this quarter, as well as the recently announced positive VOICE trial results for the primary endpoint, which marks an important step in our ultimate goal of making Vafseo standard of care for the treatment of anemia in patients on dialysis," said John P. Butler, Chief Executive Officer of Akebia. "We also continue to make strong progress advancing our rare kidney disease pipeline with the initiation of our Phase 2 basket trial evaluating ebribafusp for the treatment of three rare glomerular kidney diseases, with initial data expected in 2027. Further, enrollment continues in our Phase 2 trial of praliciguat in FSGS."
Akebia Initiates Phase 2 Trial for Ebribafusp
Akebia announced the initiation of a Phase 2 basket trial to evaluate the safety, efficacy, and pharmacokinetics of ebribafusp for the treatment of rare complement-mediated kidney diseases, including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Ebribafusp is an anti-C3d factor H fusion protein designed to inhibit complement activation in tissues without inhibiting the complement system in the blood.
Akebia and U.S. Renal Care Halt VOICE Trial
Akebia and U.S. Renal Care announced the decision by USRC Kidney Research to stop the Vafseo Outcomes In Center Experience, or VOICE, trial following a planned interim analysis. The primary investigator made the decision to stop the study after a recommendation from the Independent Data Monitoring Committee and Trial Steering Committee based on the prespecified stopping criteria and supported by findings of significantly improved safety outcomes in patients treated with Vafseo dosed three times weekly versus an erythropoiesis-stimulating agent. The VOICE trial enrolled 2,116 patients and was designed as a randomized, open-label, active controlled, non-inferiority trial sponsored by USRC to measure the safety of Vafseo administered TIW versus standard-of-care ESA using a hierarchical composite endpoint of mortality and hospitalization rates. Results of the planned interim analysis as of June 1, the data cutoff date, demonstrated that the trial met the predefined stopping criteria with a win odds of 1.16, establishing non-inferiority and superiority of the primary composite endpoint. The results further demonstrated a statistically significant decrease in hospitalizations with Vafseo versus ESA. There was no statistically significant difference between mortality rates with Vafseo versus ESA.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。